Salivary dim-light melatonin onset in early Amyotrophic Lateral Sclerosis predicts functional decline, respiratory symptom emergence, and survival

This prospective study demonstrates that an earlier salivary dim-light melatonin onset (DLMO) in early-stage amyotrophic lateral sclerosis is associated with worse functional status, faster disease progression, increased risk of respiratory symptoms, and poorer survival, suggesting DLMO serves as a non-invasive prognostic biomarker.

The Gist

The Big Picture: The Body's "Internal Clock" in ALS

Imagine your body has a master conductor, a biological clock located deep in your brain (specifically in a tiny area called the hypothalamus). This conductor tells your body when to sleep, when to wake up, and when to release a special "sleep hormone" called melatonin.

In a healthy person, this conductor is precise. As the sun goes down and the room gets dark, the conductor blows the whistle, and the pineal gland (a small gland in the brain) starts releasing melatonin. This is your signal that "it's time to wind down."

The Problem:
This study looked at people in the early stages of Amyotrophic Lateral Sclerosis (ALS), a disease that attacks the nerves controlling muscles. Scientists wanted to know: Is this internal conductor still working correctly in the early days of the disease, or is it already out of sync?

The Experiment: Listening to the "Night Whistle"

To find out, the researchers didn't just ask patients, "Do you sleep well?" (which can be unreliable). Instead, they used a biological "ear" to listen to the clock directly.

1. The Method: They asked patients to spit into small tubes at six specific times during the evening, while sitting in a very dimly lit room (like a cave with a tiny candle). This measures melatonin levels in saliva.
2. The Metric: They looked for the exact moment the melatonin levels rose above a certain threshold. In sleep science, this is called the DLMO (Dim-Light Melatonin Onset). Think of this as the exact second the conductor raises their baton to start the "sleep symphony."

The Surprising Discovery: The Clock is Running "Fast"

The researchers compared the ALS patients to healthy people of the same age.

• The Finding: The healthy people started releasing melatonin around 8:58 PM.
• The ALS Patients: They started releasing it earlier, around 8:24 PM.

The Analogy: Imagine a train station. The healthy trains (melatonin) arrive at the platform at 9:00 PM. In the ALS patients, the trains are arriving at 8:24 PM. The clock isn't just broken; it's running fast. The body is getting the "go to sleep" signal way too early, even though the patients didn't necessarily feel sleepy at that time.

Why Does This Matter? The "Crystal Ball" Effect

Here is the most important part of the study: This early clock signal is a crystal ball for the future.

The researchers tracked the patients for six months and looked at who got worse, who developed breathing trouble, and who survived. They found a clear pattern:

• The "Late" Clock is Better: Patients whose melatonin started later (closer to the normal 9:00 PM time) tended to have:

  • Better muscle strength.
  • Slower disease progression.
  • Fewer breathing problems (like shortness of breath).
  • Longer survival times.

• The "Early" Clock is Worse: Patients whose melatonin started very early (like 7:30 or 8:00 PM) tended to:

  • Lose muscle function faster.
  • Develop breathing trouble sooner.
  • Have a shorter survival time.

The Metaphor: Think of the DLMO time as a weather vane. If the vane points "Early," it's a storm warning for the patient's future health. If it points "Normal/Late," the weather is calmer for longer.

What Does This Tell Us About ALS?

For a long time, people thought sleep problems in ALS were just a side effect of being unable to move or breathe well later in the disease.

This study flips that idea. It suggests that the "conductor" in the brain is getting damaged very early, perhaps even before the muscles start to fail. The brain's network that controls sleep and time is part of the disease process from the start.

The Takeaway for Patients and Doctors

1. A New Tool: Measuring this "sleep hormone timing" (DLMO) could become a new, non-invasive tool (just a spit test!) to predict how fast a patient's disease might progress.
2. New Hope for Treatment: If the body's clock is out of sync, maybe we can fix it? Just as you can reset a watch, maybe doctors can use light therapy or timed melatonin to "reset" the patient's internal clock. If they can get the clock back on track, it might slow down the disease or improve breathing.
3. Not Just About Sleep: This isn't just about getting a good night's rest. It's about the brain's central control system. When that system gets out of sync, the whole body suffers.

Summary in One Sentence

This study found that in early ALS, the body's internal clock starts "winding down" too early, and the earlier this happens, the faster the disease tends to progress, suggesting that fixing this clock could be a new way to help patients.

Technical Summary

1. Problem Statement

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease characterized by motor neuron loss. While sleep and circadian disturbances are increasingly recognized in ALS, their timing and prognostic value in the early stages of the disease remain unclear.

• The Gap: Previous studies often attributed sleep issues in ALS to late-stage mechanical complications (e.g., respiratory failure, immobility). However, emerging evidence suggests intrinsic network dysfunction (specifically in the hypothalamus) may occur early.
• The Question: Is endogenous circadian phase timing altered in early ALS compared to healthy controls? If so, does this alteration (specifically the Dim-Light Melatonin Onset, or DLMO) serve as a non-invasive biomarker for disease progression, respiratory decline, and survival?

2. Methodology

Study Design:

• Type: Prospective, longitudinal, observational, single-center study.
• Location: Turin ALS Centre and Sleep Medicine Centre, Italy (August 2021 – August 2023).
• Participants:
  • ALS Cohort: 50 patients with early-stage ALS (symptom onset <18 months, ALSFRSr-R >36).
  • Control Cohort: 48 age- and sex-matched healthy controls (HCs) without sleep or neurological disorders.
• Exclusion Criteria: Chronic respiratory/sleep disorders, FVC <60%, use of melatonin-affecting medications (e.g., beta-blockers, antidepressants), or active cancer.

Data Collection & Biomarkers:

• Salivary Melatonin Sampling: Conducted at home under strict dim-light conditions (<10 lux). Six samples were collected relative to Habitual Sleep Onset (HSO) at intervals of -3, -2, -1, 0, +1, and +8 hours.
• DLMO Calculation: Melatonin profiles were modeled using cubic smoothing splines. DLMO was defined as the first time the fitted curve reached 3 pg/mL.
• Clinical Assessments:
  • Baseline (T0): ALSFRSr-R (total and subscores), Medical Research Council (MRC) scale, progression rate (PR), respiratory function (FVC, MEF50, PEF), polysomnography (PSG), and sleep questionnaires.
  • Follow-up (T6): Repeated clinical and respiratory assessments. A subgroup (n=28) repeated saliva sampling at T6.
• Statistical Analysis:
  • Correlations between DLMO and clinical metrics (Pearson/Spearman).
  • Logistic regression for incident respiratory symptoms (dyspnea/orthopnea).
  • Survival analysis (Kaplan-Meier and Cox proportional hazards) for time to death or tracheostomy.

3. Key Contributions

1. First Objective Characterization: This is the first study to objectively measure endogenous salivary melatonin timing (DLMO) specifically in early-stage ALS patients using a standardized home-based protocol.
2. Prognostic Utility: It establishes DLMO not just as a marker of circadian disruption, but as a predictive biomarker for functional decline, respiratory symptom emergence, and survival.
3. Decoupling from Respiratory Mechanics: The study demonstrates that circadian phase alterations exist independently of late-stage respiratory failure or standard sleep architecture changes (like sleep efficiency), suggesting an upstream hypothalamic/network dysfunction.
4. Longitudinal Stability: It shows that DLMO is a stable metric over a 6-month period in early ALS, making it a reliable baseline marker for clinical trials.

4. Key Results

A. Circadian Phase Alterations in Early ALS

• Earlier DLMO: ALS patients exhibited a significantly earlier DLMO compared to healthy controls (20:24 vs. 20:58; p=0.028) and literature norms, despite having similar Habitual Sleep Onset times and chronotypes.
• Variability: Inter-individual variability in DLMO was greater in the ALS cohort, suggesting heterogeneous circadian phase behavior.

B. Correlation with Disease Progression

• Later DLMO = Worse Outcome: Within the ALS cohort, a later baseline DLMO was strongly correlated with:
  • Worse functional status at baseline and 6 months (negative correlation with ALSFRSr-R and MRC scores).
  • Faster disease progression rates (positive correlation with PR).
  • Respiratory Emergence: A later DLMO independently predicted the development of dyspnea/orthopnea by 6 months (Adjusted OR 3.02; p=0.017).
  • Respiratory Function: Later DLMO correlated with lower FVC, MEF50, and PEF at 6 months.

C. Survival Analysis

• DLMO Threshold: Patients were dichotomized at the median DLMO (20:11).
  • Earlier DLMO (<20:11): Associated with significantly longer survival/tracheostomy-free time.
  • Later DLMO (>20:11): Associated with significantly shorter survival (Log-Rank p=0.002).
• DLMO-Sleep Onset Interval: A shorter interval between DLMO and sleep onset was also associated with poorer survival.
• Multivariate Models: These associations remained significant after adjusting for age, sex, site of onset, and disease stage.

D. Longitudinal Stability

• In the re-sampled subgroup (n=28), DLMO and other melatonin-derived metrics did not change significantly over 6 months, indicating the biomarker is stable during early disease progression.

5. Significance and Implications

Clinical Significance:

• Early Detection: DLMO alterations appear early in the disease course, potentially reflecting hypothalamic or suprachiasmatic nucleus (SCN) involvement before severe motor or respiratory decline.
• Risk Stratification: DLMO could serve as a non-invasive, physiology-anchored prognostic tool to identify patients at high risk for rapid progression and early respiratory failure.
• Trial Enrichment: Incorporating DLMO phenotyping could help stratify patients in clinical trials, ensuring more homogeneous cohorts or identifying those who might benefit from circadian-targeted interventions.

Biological Plausibility:

• The findings support the hypothesis that ALS involves early dysfunction of the hypothalamic networks regulating circadian rhythms.
• The "phase advance" (earlier DLMO) in early ALS may represent a compensatory mechanism for increased sleep pressure or early network instability.
• Circadian misalignment may bidirectionally impact respiratory control and neuroinflammation (via glymphatic clearance), accelerating disease.

Future Directions:

• Validation in larger, multi-center cohorts.
• Integration of DLMO with other biomarkers (e.g., neurofilaments, NfL) and neuroimaging of the hypothalamus.
• Testing whether phase-aligned interventions (timed light exposure, activity scheduling, or timed melatonin supplementation) can improve clinical trajectories in ALS patients with specific circadian phenotypes.

Conclusion:
The study concludes that salivary DLMO is a robust, non-invasive biomarker in early ALS. A later DLMO is a strong predictor of faster functional decline, earlier respiratory symptom emergence, and reduced survival, offering a new avenue for prognostic stratification and potential therapeutic targeting of circadian rhythms in neurodegeneration.